bioAffinity Technologies, Inc.
General ticker "BIAF" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $6.2M (TTM average)
bioAffinity Technologies, Inc. does not follow the US Stock Market performance with the rate: -26.6%.
Estimated limits based on current volatility of 6.9%: low 2.50$, high 2.87$
Factors to consider:
- Total employees count: 75 (+435.7%) as of 2023
- Top business risk factors: Insufficient capital, Limited operating history, Labor/talent shortage/retention, Regulatory and compliance, Reimbursement challenges
- Current price 82.8% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [13.14$, 51.01$]
- 2026-12-31 to 2027-12-31 estimated range: [7.50$, 28.13$]
Financial Metrics affecting the BIAF estimates:
- Negative: with PPE of -1.2 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Net income
- Negative: negative Operating cash flow
- Negative: 1.64 < Interest expense per share per price, % of 2.13
- Negative: negative Industry operating cash flow (median)
- Negative: 58.04 < Shareholder equity ratio, % of 66.40 <= 68.95
- Negative: 0 < Inventory ratio change, % of 0.15
- Negative: negative Industry operating income (median)
- Negative: -0.81 < Industry inventory ratio change (median), % of -0.51
Short-term BIAF quotes
Long-term BIAF plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2.53MM | $9.36MM | $6.16MM |
| Operating Expenses | $10.51MM | $18.32MM | $16.73MM |
| Operating Income | $-7.97MM | $-8.95MM | $-10.57MM |
| Non-Operating Income | $0.06MM | $-0.07MM | $-4.29MM |
| Interest Expense | $0.04MM | $0.09MM | $0.04MM |
| R&D Expense | $1.47MM | $1.46MM | $1.38MM |
| Income(Loss) | $-7.92MM | $-9.03MM | $-14.87MM |
| Taxes | $0.02MM | $0.01MM | $0.04MM |
| Net Income(Loss)* | $-7.94MM | $-9.04MM | $-14.91MM |
| Stockholders Equity | $4.86MM | $2.60MM | $7.28MM |
| Inventory | $0.02MM | $0.03MM | $0.05MM |
| Assets | $8.22MM | $6.51MM | $10.96MM |
| Operating Cash Flow | $-6.04MM | $-7.26MM | $-9.33MM |
| Capital expenditure | $0.02MM | $0.08MM | $0.06MM |
| Investing Cash Flow | $-2.21MM | $-0.08MM | $-0.06MM |
| Financing Cash Flow | $-0.34MM | $5.63MM | $14.73MM |
| Earnings Per Share** | $-408.28 | $-335.36 | $-129.94 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.